[A22-03] Icosapent ethyl (cardiovascular risk reduction) - Addendum to Commission A21-113
Last updated 18.02.2022
Project no.:
A22-03
Commission:
Commission awarded on 11.01.2022 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Heart and circulation
Reduction of the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides (≥ 150 mg/dL [≥ 1.7 mmol/L]) as well as
- established cardiovascular disease or
- diabetes mellitus and at least one further cardiovascular risk factor
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A21-113 | Icosapent ethyl (hypertriglyceridaemia) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2022-02-18 A G-BA decision was published.
G-BA documents on this decision